Navigation Links
Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
Date:9/4/2007

TUSTIN, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its first quarter FY 2008 financial results ended July 31, 2007 on September 10, 2007, and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Participating members of Peregrine senior management will include president and chief executive officer Steven W. King and chief financial officer Paul J. Lytle. Management will discuss financial results for the quarter and review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live or archived conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/8:30 a.m. PDT.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the call via telephone, please call the following number approximately 10 minutes prior to the scheduled time of the conference call: 1-800-860-2442 and request to join the Peregrine Pharmaceuticals conference call. A telephonic replay of the conference call will be available one hour after the conclusion of the call through September 17, 2007 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle, WARF announce partnership to lure stem cell companies
7. Doyle announces $80M renewable energy strategy
8. GE announces first installation of Discovery VCT
9. UWM announces winners of RGI awards
10. Third Wave announces two senior management appointments
11. Mirus announces new method for making antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):